Live Quote · NASDAQCDTXHealthcare · Biotechnology

Cidara Therapeutics, Inc.

$221.38▲ 0.00%(+$0.00)

TickerSpark Score

53/100

▌ Mixed

50

Valuation

20

Profitability

10

Growth

84

Health

100

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDTX research report →

52-Week Range100% of range

Low

$15.22

Current

$221.38

High

$221.42

Company Overviewwww.cidara.com

About the company

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.

CEO: Jeffrey L. Stein
IPO: 2015
Employees: 38
HQ: San Diego, CA, US

Price Chart

+719.93% · this period

Valuation

Market Cap: $5.61B
P/E: -18.79
P/S: 0.00
P/B: 8.15
EV/EBITDA: -28.82
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -60.15%
ROIC: -46.06%

Growth & Income

Revenue: $1.27M · -94.52%
Net Income: $-169,827,000 · -640.60%
EPS: $-26.75 · -409.52%
Op Income: $-176,102,000
FCF YoY: -670.21%

Performance & Tape

52W High: $221.42
52W Low: $15.22
50D MA: $187.66
200D MA: $84.67
Beta: 1.53
Avg Volume: 1.37M

Get TickerSpark's AI analysis on CDTX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	other	1,286,786	$128.679
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	sell	89,956	$0
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	sell	4,652,309	$1.03B
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	sell	5,079	$108.23K
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	other	1,286,786	$128.679
Jan 7, 26	RA CAPITAL MANAGEMENT, L.P.	director, 10 percent owner:	sell	22,200	$590.96K
Jan 7, 26	Resnick Joshua	director	sell	5,079	$108.23K
Jan 7, 26	Resnick Joshua	director	sell	22,200	$590.96K
Jan 7, 26	Spencer Ryan	director	sell	2,125	$26.86K
Jan 7, 26	Spencer Ryan	director	sell	11,100	$236.54K

Coverage · CDTX

Our CDTX coverage

Recent articles, reports, and earnings notes.

View all →

IPO

What to Watch as Alopexx, Inc. Prices Its NASDAQ IPO

Alopexx, Inc. (ALPX) is expected to list on NASDAQ on 2026-07-07, but the company has not disclosed a price range or share count yet. The setup is a binary biotech story: broad anti-infective science with a small cash base, but a long path to pivotal data and more capital.